Dynamics of Bone Turnover Markers Across the Menopausal Transition: A Retrospective Analysis

Technical Summary: Dynamics of Bone Turnover Markers Across the Menopausal Transition

Problem Statement
Menopause represents a critical physiological milestone characterized by estrogen deficiency, which leads to increased bone resorption and a heightened risk of osteoporosis. While Bone Turnover Markers (BTMs) such as Procollagen type I N-terminal propeptide (P1NP) for formation and β-isomerized C-terminal telopeptide of type I collagen (β-CTx) for resorption are established tools for monitoring bone health, the specific dynamic changes occurring during the peri-menopausal transition are often less emphasized compared to established post-menopausal osteoporosis. This study addresses the need to quantify these shifts and evaluate whether the coupling balance between bone formation and resorption is preserved or disrupted during the transition from pre- to post-menopause.

Methodology
The authors conducted a retrospective cross-sectional analysis involving 309 female subjects from the Guangzhou Women's and Children's Medical Center. Participants were stratified into three distinct groups based on menopausal status:

• Pre-menopausal (Pre-M): n = 56
• Peri-menopausal (Peri-M): n = 187
• Post-menopausal (Post-M): n = 66

Serum levels of three specific markers were measured: N-MID Osteocalcin (N-OC), P1NP, and β-CTx. Given that most BTMs exhibited non-normal distribution (assessed via Shapiro-Wilk test), the study utilized non-parametric statistical methods, including the Kruskal-Wallis test or Brown-Forsythe ANOVA, followed by Dunn's or Sidak's multiple comparisons for group differences. Correlation analyses were performed using Spearman coefficients and visualized via heatmaps.

Key Results

1. Acceleration of Bone Turnover: Post-menopausal women demonstrated significantly elevated levels of all measured markers compared to the pre-menopausal group.

   • N-MID OC: Increased from 16.17 ± 6.43 ng/mL (Pre-M) to 19.73 ± 6.80 ng/mL (Post-M).
   • P1NP: Increased from 49.08 ± 21.15 ng/mL (Pre-M) to 62.41 ± 25.15 ng/mL (Post-M).
   • β-CTx: Increased from 0.3252 ± 0.1903 ng/mL (Pre-M) to 0.4488 ± 0.2407 ng/mL (Post-M).
   • Note: The peri-menopausal group showed intermediate values that were not statistically distinct from the pre-menopausal group for most markers, suggesting the metabolic shift occurs primarily after the final menstrual period.

2. Preservation of Coupling Balance: Despite the significant rise in absolute turnover rates, the P1NP/β-CTx ratio (representing the coupling between formation and resorption) remained statistically stable across all three groups (P = 0.4607). This indicates that while the "set point" of bone remodeling is higher in post-menopause, the intrinsic balance between formation and resorption is maintained.

3. Correlation Strength: A robust positive correlation was observed between formation markers. Specifically, the correlation between P1NP and N-MID OC strengthened across the transition (r = 0.73 in Pre-M, r = 0.81 in Peri-M, and r = 0.82 in Post-M). In the post-menopausal group, β-CTx also showed strong positive correlations with both P1NP (r = 0.75) and N-MID OC (r = 0.80), reflecting a high-turnover coupling mechanism.

Significance and Claims
The paper claims that menopause triggers a synchronized acceleration of bone turnover, but crucially, the formation-resorption balance remains coupled at a higher set point rather than becoming uncoupled.

Based on the strong synchronicity between N-OC and P1NP (r = 0.82 in post-menopausal women), the authors propose a clinical optimization strategy. They suggest that because P1NP exhibits lower biological variation and is less affected by renal function than Osteocalcin, clinical screening could be streamlined. The authors claim that prioritizing P1NP and β-CTx for monitoring bone health during the menopausal transition is a cost-effective approach that reduces diagnostic costs without compromising the ability to detect rapid bone loss.

Limitations
The authors explicitly acknowledge the study's constraints:

• The cross-sectional design prevents the tracking of individual longitudinal changes.
• As a retrospective analysis, data regarding potential confounders such as BMI, serum Vitamin D, and Parathyroid Hormone (PTH) levels were not available for the cohort.
• The study focuses on the dominant impact of the menopausal transition in a "real-world healthy screening population," noting that future studies should incorporate longitudinal BMD measurements and comprehensive endocrine profiles.